Caris Life Sciences, a leading next-generation AI TechBio company and precision medicine pioneer, announced a strategic collaboration with MiBA, an innovative healthcare technology company to provide physician education and insights to accelerate research, identify and personalize treatment plans. This partnership aims to help improve patient care and advance precision medicine by supporting oncologists’ experience with Next Generation Sequencing (NGS) testing and supporting clinical research through operational optimization, BioPharma clinical trials and real-world data project identification.
“MiBA shares our commitment to innovation and improving patient outcomes,” said Caris President David Spetzler, MS, PhD, MBA. “By combining data insights with provider education, physicians will be guided to appropriate molecular testing for patients’ specific needs across multiple cancer tumor types.”
Integrating MiBA’s technology with Caris’ multimodal database provides precise, personalized treatment options for cancer patients. MiBA’s targeted, data-driven alerts provide education to oncologists when patients would be eligible based on clinical guidelines and potentially benefit from comprehensive DNA and RNA profiling, including Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) testing.
Also Read: Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer
“We’re proud to partner with Caris Life Sciences to help unlock the full potential of precision oncology,” said Jason Baroff, Managing Partner at MiBA. “Combining MiBA’s real-world insights engine with Caris’ advanced molecular capabilities will empower the oncology ecosystem with smarter, faster, and more collaborative decision-making,” said Mark Moch, Managing Partner at MiBA.
Additionally, MiBA will implement an Oncology Insights Program (OIP) in partnership with the National Community Oncology Dispensing Association (NCODA). This program will deliver meaningful provider engagement programs, education, training and actionable insights that can help advance Caris’ real-world applications of molecular profiling in the clinical setting.
SOURCE: PRNewswire